 |
|
|
|
PROCYTE ANNOUNCES APPOINTMENT OF DIRECTOR OF SALES
Redmond, Wash.—January 21, 2004—ProCyte Corporation (OTCBB: PRCY.OB),
a dermatology and
cosmetic surgery products company, today announced the appointment of
Christopher Gabanski as Director of Sales, responsible for the domestic
sales force. Mr. Gabanski brings over 25 years of sales experience in
the dermatology and skin care markets to ProCyte. Starting his career
in sales with Neutrogena, he has also held executive sales positions
with Physicians Formula, formerly a Pierre Fabre company; GenDerm,
acquired by Medicis; and most recently at Warner Chilcott dermatology
group.
“We are very pleased
to find someone with Chris’s experience in our industry. He will be
very instrumental in the further development of the existing medical
esthetics sales team as well as in managing the sales representatives
for ProCyte’s newly acquired spa distribution business,” said Jack
Clifford, Chairman and CEO. “Our domestic sales efforts have shown
improving year-over-year results since the third quarter of 2003 and
with his leadership we expect this positive momentum to continue
throughout 2004.”
ProCyte
Corporation develops and markets products based on its patented,
clinically proven Copper Peptide technology for skin health, hair care
and wound care. The Company sells directly to dermatologists, plastic
and cosmetic surgeons, spas and through licenses with strategic partners
into the consumer market, including its long-term worldwide license
agreement with Neutrogena®, a Johnson & Johnson company.
ProCyte’s products include Neova®, VitalCopper™, Simple
Solutions®
and AquaSanté®
Skin Care products; Complex Cu3® Post-Procedure
Skin Care; GraftCyte® Hair Transplant Care; and Tricomin®
Advanced Care for Thinning Hair. The Company also has the exclusive
distribution rights for Cutanix Corporation’s Quadrinone®
technology for medical and spa markets in the U.S., Canada and Puerto
Rico. Additional information is available by visiting the Company’s
website at www.procyte.com.
###
This release may contain forward-looking statements relating to the
research, development, commercialization, production, marketing and
distribution of the Company's products and future operating results,
which are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected.
The words “believe,”
“expect,” “intend,” “anticipate,” variations of such words, and similar
expressions identify forward-looking
statements, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Factors that could affect the
Company’s actual results include its ability to develop, commercialize
and produce new products; the market acceptance of existing and
potential future products; the availability, cost and timely delivery of
materials and services from and performance of third-party suppliers,
manufacturers, distributors, licensees and other collaborative partners;
the satisfaction of regulatory requirements, and the receipt, timing,
terms and conditions of required regulatory approvals. Reference is
made to the Company’s Annual Report on Form 10-K for the year ended
December 31, 2002 and its latest Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission for a more detailed
description of such factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of this release. The Company undertakes no obligation to publicly
update any forward-looking statement to reflect new information, events
or circumstances after the date of this release or to reflect the
occurrence of unanticipated events. |
|
|
|
